Gilead Sciences, Inc. (GILD.SN)
| Previous Close | 65.55 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 57.39 - 57.39 |
| 52 Week Range | 57.39 - 65.55 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 71.564B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 17.55 |
| EPS (TTM) | 3.27 |
| Earnings Date | Apr 25, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
ACCESSWIREGilead Sciences Publishes 2023 ESG Impact Report
NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's ...
PR NewswireGILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit") in Lisbon.
- PR Newswire
GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA
Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant ("Grant") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) in conjunction with the World Hepatitis Summit ("Summit"). An official announcement was made at a Gilead-hosted symposium titled "Partnering for Global Health Equity: Case Studies from Around the World," held during the World Hepatitis Summit ("Summit"
